Diagnostic HYBRIDS Releases Thyretain ™ For The Specific Detection Of Thyroid Stimulating Immunoglobulin (TSI)

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum. Thyretain is the first FDA-cleared test that specifically detects TSI and is to be used as an aid in the differential diagnosis of Graves' disease, an autoimmune thyroid disorder.